"Curt has executed a series of significant pharmaceutical collaborations that have brought renewed validation to Sangamo's innovative research and technology platform and has provided me valuable counsel on corporate strategy," said Sandy Macrae, CEO of Sangamo. "We now have a strong balance sheet which enables us to pursue our strategy to retain ownership of our own products for development and potential commercialization in our chosen therapeutic areas.
We wish Curt well in his new endeavor."Sangamo Therapeutics Announces Senior Leadership Changes
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться